What is Oxyrase?
Oxyrase operates at the intersection of microbiology and industrial biotechnology, specializing in the development of advanced anaerobic culture media. By leveraging its proprietary Oxyrase Enzyme System and OxyPlate technology, the company provides critical infrastructure for oxygen-sensitive applications. Its product suite serves a sophisticated client base, including clinical hospitals, diagnostic medical laboratories, pharmaceutical research facilities, and academic institutions. With a legacy spanning over three decades, the firm has established itself as a cornerstone provider for researchers requiring precise environmental control. Beyond standard laboratory diagnostics, Oxyrase has diversified its portfolio to include biological preservation and antioxidant solutions, ensuring the structural and chemical integrity of sensitive materials across various high-stakes industrial sectors.
How much funding has Oxyrase raised?
Oxyrase has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Oxyrase
PPP
Public-Private Partnership
What's next for Oxyrase?
The recent influx of capital positions Oxyrase to accelerate its late-stage growth strategy, focusing on the modernization of its manufacturing capabilities and the expansion of its distribution networks. As the demand for reliable anaerobic culture processes continues to rise within the pharmaceutical and clinical diagnostic fields, the company is well-positioned to capture additional market share. Future strategic initiatives will likely prioritize the integration of its antioxidant solutions into broader industrial applications, further diversifying its revenue streams. By optimizing its research methodologies and streamlining production, Oxyrase aims to reinforce its competitive advantage, ensuring that its specialized enzyme systems remain the industry standard for oxygen-sensitive research and preservation protocols.
See full Oxyrase company page
